Itch and Janus Kinase InhibitorsOriginal Article Published on 2023-02-152024-09-04 Journal: Acta dermato-venereologica [Category] 대상포진, [키워드] atopic dermatitis ITCH Janus kinase inhibitors pruritus psoriasis [DOI] 10.2340/actadv.v103.5346 PMC 바로가기 [Article Type] Original Article
Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta‐analysisReviews Published on 2022-10-022024-09-04 Journal: International journal of rheumatic diseases [Category] 대상포진, [키워드] dactylitis Enthesitis filgotinib Janus kinase inhibitors psoriasis psoriatic arthritis Tofacitinib Upadacitinib [DOI] 10.1111/1756-185X.14447 PMC 바로가기 [Article Type] Reviews
Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccinationJanus kinase inhibitor로 치료받은 류마티스 관절염 환자, BNT162b2 백신 접종 후 체액성 면역 반응 감소Article Published on 2022-08-032022-09-12 Journal: Rheumatology (Oxford, England) [Category] SARS, 진단, [키워드] Activation alteration analysed anti-spike antibodies anti-Spike IgG Anti-spike IgG antibody antibodies antibody antibody titres Arthritis B cell B cell responses B cells B-lymphocytes BNT162b2 BNT162b2 vaccine collected COVID-19 COVID-19 vaccine determine dose Efficacy elicited ELISA expression germinal centre healthy individual healthy individuals humoral humoral immune response Humoral immunity IgA antibody individuals JAK inhibitor Janus kinase Janus kinase inhibitor Janus kinase inhibitors less mRNA-based COVID-19 vaccine neutralization activity Neutralization assay neutralization capacity Patient patients patients treated plasma plasma sample quantitative PCR reduced Rheumatoid rheumatoid arthritis SARS-CoV-2 SARS-COV-2 infection shown Spike protein suppressed the SARS-CoV-2 the vaccine titre treated vaccination Vaccine Vaccines Virus neutralization was reduced was used [DOI] 10.1093/rheumatology/keab879 PMC 바로가기 [Article Type] Article
Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trialsResearch article Published on 2022-08-012022-10-05 Journal: Journal of microbiology, immunology, and infection [Category] 신약개발, 임상, 치료제, [키워드] 28-day mortality 95% CI 95% confidence interval addition adverse event Analysis article Clinical efficacy control group Controlled COVID-19 database exhibited hospitalized patient investigated Janus kinase inhibitor Janus kinase inhibitors mechanical ventilation Meta-analysis Mortality objective oral patients with COVID-19 Randomized controlled trial RCTs receiving reduce Result risk risk of death searched significantly significantly lower systematic review the study group tolerable Treatment with COVID-19 [DOI] 10.1016/j.jmii.2022.08.005 [Article Type] Research article
Safety and efficacy of long‐term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE OpenOriginal Articles Published on 2022-07-212024-09-04 Journal: Journal of gastroenterology and hepatology [Category] 대상포진, [키워드] herpes zoster Janus kinase inhibitors ulcerative colitis [DOI] 10.1111/jgh.15923 PMC 바로가기 [Article Type] Original Articles
Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trialsResearch article Published on 2022-06-032022-10-05 Journal: EClinicalMedicine [Category] 임상, [키워드] 28-day mortality 95% CI Analysis Anti-inflammatory Anti-viral Baricitinib COVID COVID19 database death Dexamethasone discharge disease duration of hospitalisation ECMO Efficacy finding funding hospitalised patient improved mortality IMV inhibitor Invasive mechanical ventilation Jak Janus kinase Janus kinase inhibitors Meta-analysis outcome patients patients with COVID-19 performed positive pressure ventilation progression PROSPERO database random-effects model randomised controlled trial RCT reduce mortality reduced Registered Respiratory failure searched severe disease shown Standard of care Standard therapy statistically significant statistically significant reduction Tocilizumab Treatment with COVID-19 [DOI] 10.1016/j.eclinm.2022.101489 [Article Type] Research article
The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-AnalysisMedicine Published on 2022-01-272022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI adverse events adverse outcomes Analysis Baricitinib baseline Clinical outcome contribute COVID-19 database decrease decreased mortality demonstrated Efficacy and safety eligible evaluated Evidence Hospitalized hospitalized patient incidence increased mortality JAK inhibitor jak inhibitors janus Janus kinase Janus kinase inhibitors kinase Meta-analysis Mortality no increase observational study outcome Patient patients with COVID-19 Randomized controlled trial RCTs Registration required Result retrieved review risk ruxolitinib Safety SARS-CoV-2 searched significant decrease significantly subgroup analysis supplemental oxygen systematic review the cytokine storm Tofacitinib Treatment Ventilation with COVID-19 [DOI] 10.3389/fmed.2021.800492 PMC 바로가기 [Article Type] Medicine
Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient ReviewsOriginal Research Published on 2022-01-112024-09-02 Journal: Frontiers in Pharmacology [Category] 대상포진, [키워드] adverse event reporting systems Janus kinase inhibitors online patient reviews potential adverse events rheumatoid arthritis [DOI] 10.3389/fphar.2021.792877 PMC 바로가기 [Article Type] Original Research
Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional StudyArticle Published on 2022-01-012023-06-11 Journal: The Journal of rheumatology [Category] B형 간염, [키워드] Hepatitis B virus Janus kinase inhibitors latent infection monoclonal antibodies rheumatoid arthritis Vasculitis [DOI] 10.3899/jrheum.210257 PMC 바로가기
A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysisOriginal Article Published on 2021-12-202024-09-04 Journal: JAAD International [Category] 대상포진, [키워드] AD, atopic dermatitis AE, adverse event AESI, adverse event of special interest atopic dermatitis clinical trial CPK, creatine phosphokinase EASI 50, ≥50% improvement in eczema area and severity index EASI 75, ≥75% improvement in Eczema Area and Severity Index EASI 90, ≥90% improvement in Eczema Area and Severity Index EASI, Eczema Area and Severity Index eczema JAK, Janus kinase Janus kinase inhibitors SAE, serious adverse event Safety TCS, topical corticosteroid TEAE, treatment-emergent adverse event Topical corticosteroids Upadacitinib vIGA-AD, validated Investigator's Global Assessment for Atopic Dermatitis [DOI] 10.1016/j.jdin.2021.11.001 PMC 바로가기 [Article Type] Original Article